The global generic drugs market size is expected to hit around USD 670.82 billion by 2030 and progressing a CAGR of 5.4% over the forecast period 2022 to 2030.
The on generic
drugs Market, which provides a business strategy, research & development
activities, concise outline of the market valuation, valuable insights
pertaining to market share, size, supply chain analysis, competitive landscape
and regional proliferation of this industry.
Download
Free Sample@ https://www.precedenceresearch.com/sample/1205
Report Scope of the Generic Drugs Market
| Report Highlights | Details |
| Market Size | US$ 670.82 Billion by 2030 |
| Growth Rate | CAGR of 5.4% From 2022 to 2030 |
| Base Year | 2021 |
| Historic Data | 2017 to 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug, Brand, Route of Drug Administration, Therapeutic Application, Distribution Channel |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
A recent
report provides crucial insights along with application based and forecast
information in the Global Generic drugs Market. The report provides a
comprehensive analysis of key factors that are expected to drive the growth of
this market. This study also provides a detailed overview of the opportunities
along with the current trends observed in the Generic drugs market.
A
quantitative analysis of the industry is compiled for a period of 10 years in
order to assist players to grow in the market. Insights on specific revenue
figures generated are also given in the report, along with projected revenue at
the end of the forecast period.
Companies
and Manufacturers Covered
The study
covers key players operating in the market along with prime schemes and
strategies implemented by each player to hold high positions in the industry.
Such a tough vendor landscape provides a competitive outlook of the industry,
consequently existing as a key insight. These insights were thoroughly analysed
and prime business strategies and products that offer high revenue generation
capacities were identified. Key players of the global Generic drugs market are
included as given below:
Generic drugs Market Key Players
- Mylan N.V.
- Abbott Laboratories
- ALLERGAN
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- STADA Arzneimittel AG
- GlaxoSmithKline Plc.
- Baxter International Inc.
- Pfizer Inc.
- Sandoz International GmbH
Market Segments
- Pure generic drugs
- Branded generic drugs
By Route of Drug Administration
- Oral
- Topical
- Parental
- Others
By Therapeutic Application
- Central nervous system (CNS)
- Cardiovascular
- Dermatology
- Oncology
- Respiratory
- Others
Key Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Report Objectives
- To define, describe, and forecast the global generic
drugs market based on product, and region
- To provide detailed information regarding the major
factors influencing the growth of the market (drivers, opportunities, and
industry-specific challenges)
- To strategically analyze micromarkets1 with respect to
individual growth trends, future prospects, and contributions to the total
market
- To analyze opportunities in the market for stakeholders
and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to
four main regions—North America,
Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively
analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as
acquisitions, expansions, new product launches, and partnerships in the generic
drugs market
Table of Content
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Generic Drugs Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19 Impact on Generic Drugs Market
5.1. Covid-19: generic drugs Industry Impact
5.2. generic drugs Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and generic drugs Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for generic drugs Market Players to deal with Covid-19 Pandemic Scenario
Chapter 6. Generic Drugs Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. The low cost of generics, as an alternative to branded drugs
6.1.1.2. Large number of patent expired branded drugs
6.1.1.3. Initiatives by governments and other regulatory bodies
6.1.2. Market Restraints
6.1.2.1. Stringent governmental regulations and adverse effects associated with drugs
6.1.3. Market Opportunities
6.1.3.1. Use of RPA to ensure regulatory and standards compliance
Chapter 7. Global Generic Drugs Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. generic drugs Market Revenue by Market Players (2017 - 2021)
7.1.1.2. generic drugs Market Revenue Market Share by Market Players (2017 - 2021)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
Chapter 8. Global Generic Drugs Market, By Drug Type
8.1. generic drugs Market, by Drug Type, 2017-2030
8.1.1. Simple Generics
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Super Generics
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Generic Drugs Market, By Brand
9.1. generic drugs Market, by Brand, 2017-2030
9.1.1. Pure generic drugs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Branded generic drugs
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Generic Drugs Market, By Route of Drug Administration
10.1. generic drugs Market, by Route of Drug Administration, 2017-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Topical
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Parental
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Generic Drugs Market, By Therapeutic Application
11.1. generic drugs Market, by Therapeutic Application, 2017-2030
11.1.1. Central nervous system (CNS)
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Cardiovascular
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Dermatology
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Oncology
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Respiratory
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Generic Drugs Market, By Distribution Channel
12.1. generic drugs Market, by Distribution Channel, 2017-2030
12.1.1. Hospitals Pharmacies
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Retail Pharmacies
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Others
12.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Generic Drugs Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue Forecast by Drug Type(2017-2030)
13.1.2. Market Revenue Forecast by Brand (2017-2030)
13.1.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.1.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.1.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.1.6. U.S
13.1.6.1. Market Revenue Forecast (2017-2030)
13.1.7. Canada
13.1.7.1. Market Revenue Forecast (2017-2030)
13.2. Europe
13.2.1. Market Revenue Forecast by Drug Type (2017-2030)
13.2.2. Market Revenue Forecast by Brand (2017-2030)
13.2.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.2.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.2.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue Forecast (2017-2030)
13.2.7. Germany
13.2.7.1. Market Revenue Forecast (2017-2030)
13.2.8. France
13.2.8.1. Market Revenue Forecast (2017-2030)
13.2.9. Rest of EU
13.2.9.1. Market Revenue Forecast (2017-2030)
13.3. Asia Pacific (APAC)
13.3.1. Market Revenue Forecast by Drug Type (2017-2030)
13.3.2. Market Revenue Forecast by Brand (2017-2030)
13.3.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.3.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.3.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.3.6. China
13.3.6.1. Market Revenue Forecast (2017-2030)
13.3.7. India
13.3.7.1. Market Revenue Forecast (2017-2030)
13.3.8. Japan
13.3.8.1. Market Revenue Forecast (2017-2030)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue Forecast (2017-2030)
13.4. LATAM
13.4.1. Market Revenue Forecast by Drug Type (2017-2030)
13.4.2. Market Revenue Forecast by Brand (2017-2030)
13.4.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.4.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.4.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.4.6. Brazil
13.4.6.1. Market Revenue Forecast (2017-2030)
13.4.7. Rest of LATAM
13.4.7.1. Market Revenue Forecast (2017-2030)
13.5. Middle East and Africa (MEA)
13.5.1. Market Revenue Forecast by Drug Type (2017-2030)
13.5.2. Market Revenue Forecast by Brand (2017-2030)
13.5.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.5.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.5.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.5.6. GCC
13.5.6.1. Market Revenue Forecast (2017-2030)
13.5.7. North Africa
13.5.7.1. Market Revenue Forecast (2017-2030)
13.5.8. South Africa
13.5.8.1. Market Revenue Forecast (2017-2030)
13.5.9. Rest of MEA
13.5.9.1. Market Revenue Forecast (2017-2030)
Chapter 14. Company Profiles
14.1. Abbott Laboratories
14.1.1. Company Overview, Business Information, Regional Presence
14.1.2. Product Portfolio Analysis
14.1.2.1. Product Details, Specification, Application
14.1.3. Revenue, Price, and Gross Margin (2017-2021)
14.1.4. Recent Developments and Strategies
14.2. Teva Pharmaceutical Industries Ltd.
14.2.1. Company Overview, Business Information, Regional Presence
14.2.2. Product Portfolio Analysis
14.2.2.1. Product Details, Specification, Application
14.2.3. Revenue, Price, and Gross Margin (2017-2021)
14.2.4. Recent Developments and Strategies
14.3. ALLERGAN
14.3.1. Company Overview, Business Information, Regional Presence
14.3.2. Product Portfolio Analysis
14.3.2.1. Product Details, Specification, Application
14.3.3. Revenue, Price, and Gross Margin (2017-2021)
14.3.4. Recent Developments and Strategies
14.4. Sandoz International GmbH
14.4.1. Company Overview, Business Information, Regional Presence
14.4.2. Product Portfolio Analysis
14.4.2.1. Product Details, Specification, Application
14.4.3. Revenue, Price, and Gross Margin (2017-2021)
14.4.4. Recent Developments and Strategies
14.5. Mylan N.V.
14.5.1. Company Overview, Business Information, Regional Presence
14.5.2. Product Portfolio Analysis
14.5.2.1. Product Details, Specification, Application
14.5.3. Revenue, Price, and Gross Margin (2017-2021)
14.5.4. Recent Developments and Strategies
14.6. STADA Arzneimittel AG
14.6.1. Company Overview, Business Information, Regional Presence
14.6.2. Product Portfolio Analysis
14.6.2.1. Product Details, Specification, Application
14.6.3. Revenue, Price, and Gross Margin (2017-2021)
14.6.4. Recent Developments and Strategies
14.7. Baxter International Inc.
14.7.1. Company Overview, Business Information, Regional Presence
14.7.2. Product Portfolio Analysis
14.7.2.1. Product Details, Specification, Application
14.7.3. Revenue, Price, and Gross Margin (2017-2021)
14.7.4. Recent Developments and Strategies
14.8. Eli Lilly and Company
14.8.1. Company Overview, Business Information, Regional Presence
14.8.2. Product Portfolio Analysis
14.8.2.1. Product Details, Specification, Application
14.8.3. Revenue, Price, and Gross Margin (2017-2021)
14.8.4. Recent Developments and Strategies
14.9. GlaxoSmithKline Plc.
14.9.1. Company Overview, Business Information, Regional Presence
14.9.2. Product Portfolio Analysis
14.9.2.1. Product Details, Specification, Application
14.9.3. Revenue, Price, and Gross Margin (2017-2021)
14.9.4. Recent Developments and Strategies
14.10. Pfizer Inc.
14.10.1. Company Overview, Business Information, Regional Presence
14.10.2. Product Portfolio Analysis
14.10.2.1. Product Details, Specification, Application
14.10.3. Revenue, Price, and Gross Margin (2017-2021)
14.10.4. Recent Developments and Strategies
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments